Literature DB >> 24619626

Re-evaluating the concept of "dominant/index tumor nodule" in multifocal prostate cancer.

Cheng Cheng Huang1, Fang-Ming Deng, Max X Kong, Qinhu Ren, Jonathan Melamed, Ming Zhou.   

Abstract

Prostate cancer (PCa) often presents as a multifocal disease with heterogeneity in Gleason score (GS) and genetic alterations. Dominant/index tumor nodule (DN), the largest nodule in a multifocal disease, is presumed to harbor the most aggressive biological behavior and therefore dictate the overall clinical behavior of PCa. In this study, we examined the pathological features of DN and re-evaluated the validity of the "DN" concept in multifocal PCa. A total of 201 consecutive radical prostatectomy specimens were totally submitted and examined. All independent cancer foci were recorded with prognostically important pathological parameters. Unifocal and multifocal disease was present in 25 (12.4 %) and 176 (87.6 %) cases, respectively. In 20 (11.3 %) multifocal cases, the highest GS, the largest tumor volume (TV), and extraprostatic extension (EPE) did not concur in the same tumor nodules. Non-DNs had a higher GS and EPE in 13 cases each and had both the highest GS and EPE in 5 cases. In the majority of multifocal prostate cancer (88.7 %), DNs have the highest GS and EPE. In these cases, DN is still a valid concept and can be used for assigning overall GS and procuring tissue for research. However, in a significant number of cases (11.3 %), the largest TV, the highest GS, and EPE did not concur in the same tumor nodules. In these cases, pathologists should de-emphasize the concept of DN. Instead, they should place the emphasis on the multifocal nature of the disease and document the pathological features of all independent tumor foci that have the largest TV, the highest GS, and EPE.

Entities:  

Mesh:

Year:  2014        PMID: 24619626     DOI: 10.1007/s00428-014-1557-y

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  40 in total

Review 1.  International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 3: extraprostatic extension, lymphovascular invasion and locally advanced disease.

Authors:  Cristina Magi-Galluzzi; Andrew J Evans; Brett Delahunt; Jonathan I Epstein; David F Griffiths; Theo H van der Kwast; Rodolfo Montironi; Thomas M Wheeler; John R Srigley; Lars L Egevad; Peter A Humphrey
Journal:  Mod Pathol       Date:  2010-08-27       Impact factor: 7.842

2.  Carcinoma of the prostate: prognostic evaluation of certain pathologic features in 208 radical prostatectomies. Examined by the step-section technique.

Authors:  D P Byar; F K Mostofi
Journal:  Cancer       Date:  1972-07       Impact factor: 6.860

3.  Correlations between atypical primary hyperplasia and carcinoma of the prostate. A histological study of 180 total prostatectomies.

Authors:  H Kastendieck
Journal:  Pathol Res Pract       Date:  1980-11       Impact factor: 3.250

4.  The combined percentage of Gleason patterns 4 and 5 is the best predictor of cancer progression after radical prostatectomy.

Authors:  Liang Cheng; Michael O Koch; Beth E Juliar; Joanne K Daggy; Richard S Foster; Richard Bihrle; Thomas A Gardner
Journal:  J Clin Oncol       Date:  2005-05-01       Impact factor: 44.544

5.  Detailed mapping of prostate carcinoma foci: biopsy strategy implications.

Authors:  M E Chen; D A Johnston; K Tang; R J Babaian; P Troncoso
Journal:  Cancer       Date:  2000-10-15       Impact factor: 6.860

6.  Extranodal extension in lymph node-positive prostate cancer.

Authors:  L Cheng; T M Pisansky; D M Ramnani; B C Leibovich; J C Cheville; J Slezak; E J Bergstralh; H Zincke; D G Bostwick
Journal:  Mod Pathol       Date:  2000-02       Impact factor: 7.842

7.  Histological grade heterogeneity in multifocal prostate cancer. Biological and clinical implications.

Authors:  E T Ruijter; C A van de Kaa; J A Schalken; F M Debruyne; D J Ruiter
Journal:  J Pathol       Date:  1996-11       Impact factor: 7.996

8.  Percentage of Gleason pattern 4 and 5 predicts survival after radical prostatectomy.

Authors:  Liang Cheng; Darrell D Davidson; Haiqun Lin; Michael O Koch
Journal:  Cancer       Date:  2007-11-01       Impact factor: 6.860

9.  Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer.

Authors:  J I Epstein; P C Walsh; M Carmichael; C B Brendler
Journal:  JAMA       Date:  1994-02-02       Impact factor: 56.272

10.  Pathological features of hereditary prostate cancer.

Authors:  S I Bastacky; K J Wojno; P C Walsh; M J Carmichael; J I Epstein
Journal:  J Urol       Date:  1995-03       Impact factor: 7.450

View more
  11 in total

1.  Volumetric modulated arc therapy planning for primary prostate cancer with selective intraprostatic boost determined by 18F-choline PET/CT.

Authors:  Yu Kuang; Lili Wu; Emily Hirata; Kyle Miyazaki; Miles Sato; Sandi A Kwee
Journal:  Int J Radiat Oncol Biol Phys       Date:  2015-04-01       Impact factor: 7.038

2.  Total intraglandular and index tumor volumes predict biochemical recurrence in prostate cancer.

Authors:  Su-Jin Shin; Cheol Keun Park; Sung Yoon Park; Won Sik Jang; Joo Yong Lee; Young Deuk Choi; Nam Hoon Cho
Journal:  Virchows Arch       Date:  2016-06-15       Impact factor: 4.064

3.  [Focal therapy of prostate cancer].

Authors:  R Ganzer; T Franiel; J Köllermann; T Kuru; D Baumunk; A Blana; B Hadaschik; J von Hardenberg; T Henkel; K-U Köhrmann; U-B Liehr; S Machtens; A Roosen; G Salomon; H-P Schlemmer; L Sentker; J Wendler; U Witzsch; M Schostak
Journal:  Urologe A       Date:  2017-10       Impact factor: 0.639

4.  MRI-guided focal boost to dominant intraprostatic lesion using volumetric modulated arc therapy in prostate cancer. Results of a phase II trial.

Authors:  Almudena Zapatero; Maria Roch; Pablo Castro Tejero; David Büchser; Carmen Martin de Vidales; Saturnino González; Pablo Rodríguez; Luis Alberto San Jose; Guillermo Celada; Maria Teresa Murillo
Journal:  Br J Radiol       Date:  2021-09-19       Impact factor: 3.039

5.  Histopathological Study of the Prostate Cancer Growth Patterns in Relation with the Grading Systems.

Authors:  Tudor Cristian Timotei Popescu; Alex Emilian Stepan; Mirela Marinela Florescu; Cristiana Eugenia Simionescu
Journal:  Curr Health Sci J       Date:  2022-03-31

6.  Stereotactic radiotherapy with focal boost for intermediate and high-risk prostate cancer: Initial results of the SPARC trial.

Authors:  Luke Nicholls; Yae-Eun Suh; Ewan Chapman; Daniel Henderson; Caroline Jones; Kirsty Morrison; Aslam Sohaib; Helen Taylor; Alison Tree; Nicholas van As
Journal:  Clin Transl Radiat Oncol       Date:  2020-10-20

Review 7.  Prostate irradiation with focal dose escalation to the intraprostatic dominant nodule: a systematic review.

Authors:  Thomas Feutren; Fernanda G Herrera
Journal:  Prostate Int       Date:  2018-03-27

8.  Template guided transperineal saturation biopsy of the prostate: lessons for focal and urethra-sparing high-dose-rate brachytherapy for localized prostate cancer.

Authors:  Sergey Nikolaevich Novikov; Sergey Vasilevich Kanaev; Roman Vladimirovich Novikov; Nikolay Dmitrievich IIlin; Anna Sergeevna Artemieva; Alexnder Olegovich Ivantcov; Evgeniy Alexandrovich Piskunov; Mariya Yurievna Gotovchikova
Journal:  J Contemp Brachytherapy       Date:  2016-04-19

9.  Focal application of low-dose-rate brachytherapy for prostate cancer: a pilot study.

Authors:  S Sara Mahdavi; Ingrid T Spadinger; Septimiu E Salcudean; Piotr Kozlowski; Silvia D Chang; Tony Ng; Julio Lobo; Guy Nir; Hamid Moradi; Michael Peacock; W James Morris
Journal:  J Contemp Brachytherapy       Date:  2017-06-13

10.  The 2019 International Society of Urological Pathology (ISUP) Consensus Conference on Grading of Prostatic Carcinoma.

Authors:  Geert J L H van Leenders; Theodorus H van der Kwast; David J Grignon; Andrew J Evans; Glen Kristiansen; Charlotte F Kweldam; Geert Litjens; Jesse K McKenney; Jonathan Melamed; Nicholas Mottet; Gladell P Paner; Hemamali Samaratunga; Ivo G Schoots; Jeffry P Simko; Toyonori Tsuzuki; Murali Varma; Anne Y Warren; Thomas M Wheeler; Sean R Williamson; Kenneth A Iczkowski
Journal:  Am J Surg Pathol       Date:  2020-08       Impact factor: 6.298

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.